Md Jashim Uddin, Ph.D.

Md Jashim Uddin, Ph.D.

Associate Professor, Research - Biochemistry

Jashim Uddin earned his BS (Honors) and MS degrees in Chemistry at the Dhaka University, Bangladesh. He conducted his organic chemistry research studies with Dr. Giasuddin Ahmed as the partial fulfillment for his MS degree. After completion of his MS studies, he started his professional career with an industrial position at the Bexmico Pharmaceuticals, Bangladesh, where he was appointed as a Production Officer and Shift In-charge of Good Manufacturing Practice (GMP) production of amoxicillin trihydrate and ciprofloxacin hydrochloride under the United States Pharmacopeia. Because of his high research interests, he accepted a research position at the Beximco Pharma Center for Bio and Industrial Research, a joint research and development laboratory of Beximco Pharmaceuticals, Bangladesh and Ciba Specialty Chemicals, Switzerland, where he was appointed as a Research Chemist of process chemistry of organo-color compounds. Jashim joined the Bangladesh Civil Service (16th BCS) at the Department of Education (called Ministry of Education) of the Government of the People’s Republic of Bangladesh in 1996, where he was appointed as a tenure-track faculty member (position title: Lecturer of Chemistry) at the Cox’s Bazar Government College of the National University of Bangladesh.

In 1997, he was awarded the Japanese Government (MONBUSHO) scholarship for his doctoral studies with Dr. Iwao Yamamoto, and earned his PhD degree in Organic Chemistry from the Shinshu University, Japan.

In 2002, Jashim was awarded the Alberta Heritage Foundation for Medical Research (AHFMR) scholarship for his 1stpostdoctoral studies in medicinal chemistry with Dr. Edward Knaus at the University of Alberta, Canada. Later, he accepted his 2ndpostdoctoral position with Dr. Lawrence J. Marnett at the Vanderbilt University, USA, in 2004, to study chemical biology and biomedical engineering.

In 2005, Jashim accepted faculty position at the Vanderbilt University School of Medicine and appointed as an Assistant Professor, Research – Biochemistry. His current faculty title at the Vanderbilt University is Associate Professor, Research – Biochemistry. Jashim is interested in novel fluorescent/radiolabeled small molecules or smart nanomedicines for diagnostic and therapeutic targeting of cyclooxygenase-2 (COX-2) in cancer. His work established proof-of-principle for cancer imaging and therapy using COX-2 as a target to deliver imaging and therapeutic agents to tissues containing elevated levels of the enzyme. He discovered fluorocoxibs (fluorescently labeled COX-2 probes) for visualization of tumors, and chemocoxibs (cytotoxic COX-2 ligands) for tumor growth inhibition. His recent works reengineered fluorocoxibs and chemocoxibs into smart nanoparticles that are validated for simultaneous targeting of COX-2 by a diagnostic and a therapeutic agent in cancer. He is currently focused on nanoparticle-based smart medicines that can be applied in image guidance and selective delivery of therapies to the tumors. The nano-platform he discovered can provide opportunities to develop novel strategies to accomplish tremendous improvement of today’s personalized medicine.

 

SELECTED PRESS RELEASE / MEDIA COVERAGES

· COX-2 ‘conjugate’ may slow growth of some tumors: study. VUMC Reporter Jan. 19, 2017.

· Anticancer drug conjugate selectively targets and inhibits the intracellular protein COX-2 in in vivo tumors. Chemical Research in Toxicology, Nov 21, page 1791, 2016.

· Imaging probe for retinal disease. VUMC Reporter Oct. 12, 2016.

· Lit up COX-2 cancer probe. VUMC Reporter Jun 12, Page 2, 2015.

· Challenge puts technology transfer ingenuity on display. VUMC Reporter, Apr 17, Page 6, 2015.

· Molecular imaging of inflammation and carcinogenesis. Cancer Prevention Research, 4, 1523, 2011.

· Imaging agents offer new views of inflammation, cancer. Science Daily Oct 7, 2011.

· New views of inflammation and cancer. VUMC Reporter Oct 21, Page 2, 2011.

· Imaging of inflammation and cancer. Cancer Research. 70, 3418, 2010

· Fluorescent agents target enzyme in cancer Cells. Chemical and Engineering News 88(7), 12, 2010.

· Novel imaging agents shine light on developing tumors. VUMC Reporter May 7, Page 1, 2010.

· Fluorescent compounds make tumor glow, cancer. Science Daily April 29, 2010.

· Fluorescent inhibitors hold promise for early-stage tumor detection. Medical News April 29, 2010.                                                                            

 

SCHOLARSHIPS / AWARDS

1997- 2001 Japanese Government MONBUSHO – Graduate Scholarship Award
2001- 2004 Canadian AHFMR – Postdoctoral Fellowship Award                                                       

 

ACHIEVEMENTS HIGHLIGHTS

1. Fluorocoxib A (Xenolight®RediJect COX-2 Probe): Fluorocoxib A, the first COX-2-targeted optical imaging, is discovered. Fluorocoxib A is licensed to Perkin Elmer Company, USA, for commercialization for pre-clinical detection of inflammation and cancer. 

2. Certificate of Recognition to Uddin, MJ.: A ‘Certificate of recognition’ was awarded by OMICS Scientific Community for Uddin’s extraordinary scientific contributions in COX-2 targeted delivery of imaging agents.

3. Perspective on Uddin, MJ.: A perspective was published by scientific community recognizing Uddin’s contribution to the biomedical imaging field.

       

REVIEWER - SCIENTIFIC JOURNALS

Nature Communications, 2014 - present

PLOS one, 2008 - present

Journal of Medicinal Chemistry, 2005 – present

Bioorganic and Medicinal Chemistry, 2005 – present

Bioorganic and Medicinal Chemistry Letters, 2005 – present

Journal of Heterocyclic Chemistry, 2005 – present

European Journal of Medicinal Chemistry, 2005 – present

 

REVIEWER – RESEARCH GRANTS

Multidisciplinary Research Grant, North Carolina Biotechnology Center, 2005 - present

 

DISSERTATIONS

1. Ph.D.: Organic Chemistry. Synthesis and Structure of Chiral Heterobicycles and Their Application in Asymmetric Synthesis. Professor Iwao Yamamoto, Advisor.

2. M.S.: Organic Chemistry. Studies on Reactions of Substituted Chacones with Acyclic 1,3-Diketones. Professor M. G. Ahmed, Advisor.

 

SCIENTIFIC COMMUNITY SERVICES

Chair of Executive Committee: Network for Translational Research (NTR) Chemistry Core, National Institutes of Health (NIH), National Cancer Institute (NCI), USA, 2012—2013

 

BOOK CHAPTERS

Aldrich, M. B., Rasmussen, J. C., Azhdarinia, A., Joshi, B., Uddin, M. J., Akers, W. J., Culver, J. P., Smith, A., Bouchard, J-P., Kurabayashi, K. Translational Research in Biophotonics, 2013, Chapter 3, Page 29-67; National Cancer Institute, eBooks DOI: 10.1117/3.1002515.ch3; SPIE PRESS, Bellingham, Washington USA,  

 

PATENTS

Methods and compositions for diagnostic and therapeutic targeting of COX-2 (US 0254910) June 2010. Disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also, provided are methods for using the disclosed compositions for diagnosing (i.e. by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activities.

Fluorocoxib A loading into ROS-responsive nano-particles (US 62/191367) February 2015. Disclosed are compositions and methods for making and using the disclosed compositions. In a further aspect, disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle.

Composition and method for detecting hypoxia (US 62/156055) November 2015. Disclosed subject matter comprised diagnostic agent conjugated to a hypoxia marker moiety. Disclosed methods and compositions for diagnosing (i.e. by optical imaging) hypoxic cells and/or treating a disorder associated with hypoxia.

Activatable compounds and methods for cancer imaging (US 62/316935) June 2016. Disclosed materials are diagnostic agents comprised of a radical and a fluorophore moiety.  Disclosed technology methods for developing smart probes enable visualization of cells associated with cancer, inflammation, or disorders associated with carcinogenesis.

Methods and compositions for diagnostic targeting of COX-1 by PET imaging agents (a probationary patent application filed in February 2017). Disclosed subject matter comprised F-18 radiopharmaceuticals for imaging COX-1 in ovarian cancer.  Disclosed technology includes novel radiochemical methods for radiolabeling of furanone-containing compounds useful for detection/intervention of ovarian carcinogenesis.

 

Ph.D. STUDENT SUPERVISED/MENTORED

Paola Malerba – Design, synthesis and in vivo evaluation of COX inhibitors also as novel specific PET imaging agents in cancer and inflammation models – Ph.D. Dissertation 2013

Vanderbilt University, USA, and University of Bari, Aldo Moro, Italy

 

SCIENTIFIC PUBLICATIONS

Search For Uddin Articles on PubMed

2017

Bedse, G., Hartley, N. D., Neale, E., Gaulden, A., Patrick, T., Kingsley, P., Uddin, M. J., Plath, N., Marnett, L.J., and Patel, S. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biological Psychiatry, 2017, 82, 488-499.

Bluett, R., Baldi, R., Haymer, A., Hartley, N., Marcus, D., Bey, R. M., Shonesy, B., Uddin, M. J., Lawrence J. Marnett, L. J., Colbran, R., Winder, D. Patel, S. Endocannabinoid mechanism promoting resilience to traumatic stress. Nature Communications, 2017, 8, 14782.

 

2016

Uddin, M. J., Crews, B. C., Xu, S., Ghebreselasie, K., Daniel, C.K., Kingsley, P. J., and Marnett, L.J., Antitumor activity of cytotoxic cyclooxygenase-2 inhibitors. ACS Chemical Biology, 2016, 11, 3052-3060.

Uddin, M. J.,* Moore, C. E., Crews, B. C., Daniel, C. K., Ghebreselasie, K., McIntyre, J. O., Marnett, L. J., and Jayagopal, A., Fluorocoxib A Enables Targeted Detection of Cyclooxygenase-2 in Laser–Induced Choroidal Neovascularization, Journal of Biomedical Optics, 2016, 21(9), 90503. (*Corresponding Author). See Reporter Article

Adeniji, A., Uddin, M. J., Zang, T., Tamae, D., Wangtrakuldee, P., Marnett, L. J., Penning, T. M., Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid As a Potent and Selective AKR1C3 Inhibitor. Journal of Medicinal Chemistry, 2016, 59(16), 7431-7444.

Foster, D.J., Wilson, J.M., Remke, D.H., Mahmood, M.S., Uddin, M.J., Wess, J., Patel, S., Marnett, L.J., Niswender, C.M., Jones, C.K., Xing, Z., Lindsley, C.W., Rook, J.M., Conn, P.J. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron, 2016, 91(6), 1244-1252. 

Uddin, M. I., Evans, S. M., Craft, J. R., Capozzi, M. E., McCollum, G. W., Rong Yang, R., Lawrence J. Marnett, L. J., Uddin, M. J., Ashwath Jayagopal, A., and Penn, J. S. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen Induced Retinopathy. Scientific Reports, 6, 31011; doi: 10.1038/srep31011 (2016) 

Uddin, M. J., Werfel, T. A., Crews, B. C., Gupta, M. K., Marnett, L. J., Duvall, C. L. Fluorocoxib A loaded into ROS-responsive nanoparticles enables in vivo targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials, 2016, 92, 71-80.

 

2015

Uddin, M. J.,* Crews, B. C., Ghebreselasie, K., Daniel, C. K., Kingsley, P. J., Xu, S., Marnett, L. J. Targeted delayed imaging of cancer by fluoroocoxib C, a near-infrared cyclooxygenase-2 probe. Journal of Biomedical Optics, 2015, 20(5), 050502 (*Corresponding Author).

Wilson, A. J., Fadare, O., Beeghly-Fadeil, A., Son, D-S., Liu, Q., Zhao, S., Saskowski, J., Uddin, M. J., Daniel, C., Crews, B. C., Lehmann, B. D., Pietenpol, J., Crispens, M. A., Marnett, L. J., Khabele, D. Genetic disruption of COX-1 inhibits multiple oncogenic pathways in high-grade serous ovarian cancer. Oncotarget, 2015, 6(25), 21353-21368.

Ra, H., González-González, E., Uddin, M. J., King, B. L., Lee, A., Ali-Khan, I., Marnett, L. J., Tang, J., and Contag, C. H. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluroocoxib. A. Neoplasia, 2015, 17(2), 201-207.

Uddin, M. I., Evans, S. M., Craft, J. R., Marnett, L. J., Uddin, M. J.* Joyagopal, A*. Applications of azo-based probes for imaging retinal hypoxia. ACS Medicinal Chemistry Letters, 2015, 6 (4), 445–449 (*Corresponding Author)

 

2014

Uddin, M. J., Elleman, A. V., Ghebreselasie,K., Daniel, C.K., Crews,B. C., Nance, K. D.,  Huda, T., Rouzer, C. A., and Marnett,L.J. Design of fluorine-containing 3,4-diaryl-2(5H)-ones as selective COX-1 inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 1254-1258

Uddin, M. J.,* Crews,B.C., Huda, I., Ghebreselasie,K., Daniel, C.K., and Marnett,L.J. Trifluoromethyl fluorocoxib A detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Medicinal Chemistry Letters, 2014, 5, 445-450 (*Corresponding Author), [Note – cover article]

Perrone, M. G., Malerba, P., Uddin, M. J., Vitale, P., Panella, A., Crews, B. C., Daniel, C. K.,  Ghebreselasie,K., Nickels, M., Tantawy, M. N., Manning, H. C., Marnett, L. J., Scilimati, A. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation European Journal of Medicinal Chemistry 2014, 80, 562-568.

 

2013

Uddin, M. J., Crews, B. C., Ghebreselasie,K., and Marnett, L. J. Design, Synthesis, and Structure—Activity Relationship Studies of Fluorescent Inhibitors of Cycloxygenase-2 as Targeted Optical Imaging Agents. Bioconjugate Chemistry, 2013, 24, 712-723.

Blobaum, A.,* Uddin, M. J.,* Felts, A. S.; Crews, B. C.; Rouzer, C. A.; Marnett, L. J. The 2¢-trifluoromethyl analog of indomethacin as a potent and selective COX-2 inhibitor. ACS Medicinal Chemistry Letters, 2013, 4, 486-490. (*Joint 1st Author)

Cekanova, M., Uddin, M. J.; Bartges, J. W.; Callens, A.; Legendre, A. M.; Rathore, K.; Wright, L.; Carter, A.; Marnett, L. J. Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo by Fluorocoxib A. Cancer Prevention Research, 2013, 6, 466-476.

 

2012

Cekanova, M., Uddin, M. J.; Legendre, A. M.; Galyon, G.; Bartges, J. W.; Callens, A.; Martin-Jimenez, T.; Marnett, L. J. Single-dose safety and pharmacokinetic evaluation of Fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model. Journal of Biomedical Optics, 2012, 17(11), 116002-116011.

Aldrich, M. B., Milton V. Marshall, M. V., Sevick-Muraca, E. M., Lanza, G., Kotyk, J., Joseph Culver, J., Wang, L. V., Uddin, M. J. et al. Seeing it through: translational validation of new medical imaging modalities. Biomecial Optics Express, 2012, 3(4), 764-776.

 

2011

Uddin, M. J., Crews, B. C., Ghebreselasie,K., Huda I., Kingsley, P. J., Ansari, M. S., Tantawy, M. N., Reese, J., and Marnett, L. J. Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer. Cancer Prevention Research, 2011, 4, 1536-1545. [Note – (i) cover article; (ii) ‘perspective on Uddin et al’; (iii) several newspaper headlines].

Uddin, M. J., Crews,B.C., Ghebreselasie,K., Tantawy, M. N., and Marnett,L.J. [123I]-Celecoxib Analogs as SPECT Tracer of Cyclooxygenase-2 (COX-2) in Inflammation. ACS Medicinal Chemistry Letters, 2010, 2, 160-164.

 

2010

Uddin, M. J., Schulte, M. I., Maddukuri, L., Harp, J., and Marnett, L. J. Semisynthesis of 6-Chloropurine-2′-deoxyriboside 5′-Dimethoxytrityl 3′-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its Use in the Synthesis of Fluorescently-Labeled Oligonucleotides. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 831-840.

Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingsley, P. J., Piston, D. W., Gordon, L., McIntyre, O., Matrisian, L., Dannenberg, A. J., Subbarahmiah, K., and Marnett, L. J. Selective visualization of Cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Research, 2010, 70(9), 3618-3627. [Note – published with several newspaper headlines]

Uddin, MJ,  Smithson, DC, Brown, KM, Crews, BC, Connelly, M, Zhu, F, Marnett, LJ, Guy, RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg Med Chem Lett, 2010, 20(5), 1787-1791.

 

2009

Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 387-393.

Konkle, ME, Hargrove, TY, Kleshchenko, YY, von Kries, JP, Ridenour, W,  

Uddin, M.J., Caprioli, RM, Marnett, LJ, Nes, WD, Villalta, F, Waterman, MR, Lepesheva, GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J Med Chem, 2009, 52(9), 2846-2853.

 

2008

Uddin, M. J., Marnett, LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org Lett, 2008, 10(21), 4799-4801.

 

2006

Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood, 2006, 13, 4059-4062.

 

2005

Uddin, M. J.; Rao, P. N. P.; McDonald, R.; Knaus, E. E. Design and Synthesis of (E)-1,1,2-triarylethenes: Novel Inhibitors of the Cyclooxygenase-2 (COX-2) Isozyme. Bioorganic & Medicinal Chemistry Letters 2005, 15, 439-442.

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design and Synthesis of (Z)-1,2-Diphenyl-1-(4-methanesulfonamidophenyl-2-alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenyl-2-alk-1-enes: Novel Inhibitors of Cyclooxygenase-2 (COX-2) with Antiinflammatory and Analgesic Activity. Bioorganic & Medicinal Chemistry 2005, 13, 417-424.

 

 2004

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design and Synthesis of Acyclic Triaryl (Z)-Olefins: A Novel Class of Cyclooxygenase-2 (COX-2) Inhibitors. Bioorganic & Medicinal Chemistry 2004, 12, 5929-5940.

Uddin, M. J.; Rao, P. N. P.; McDonald, R.; Knaus, E. E. A New Class of Acyclic 2-alkyl-1,1,2-Triaryl (Z)-Olefins as Selective Cyclooxygenase-2 (COX-2) inhibitors. Journal of Medicinal Chemistry 2004, 47, 6108-6111.

Uddin, M. J.; Rao, P. N. P.; Rahim, M. A.; McDonald, R.; Knaus, E. E. A New Class of Acyclic 2-alkyl-1,2-diaryl (E)-Olefins as Selective Cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & Medicinal Chemistry Letters 2004, 14, 4911-4914.

Rao, P. N. P.; Uddin, M. J.; Knaus, E. E. Design, Synthesis and Structure-Activity Relationship (SAR) Studies of 3,4,6-Triphenylpyran-2-ones as Selective Cyclooxygenase-2 (COX-2) Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 3972-3990.

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett 2004, 9, 1513-1516.

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design of Acyclic Triaryl Olefins: A New Class of Potent and Selective Cyclooxygenase-2 (COX-2) Inhibitors. Bioorganic & Medicinal Chemistry Letters 2004, 14, 1953-1956.

 

2003

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry 2003, 40, 861-868.

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Celecoxib Analogs as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide Pharmacophore by a Sulfonylazide Bioisostre. Bioorganic & Medicinal Chemistry 2003, 11, 5273-5280.

 

2000

Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I. Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications 2000, 6, 505-510

Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I. Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications 2000, 6, 113-118

Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I. “Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure a-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity.” Synthesis 2000, 3, 365-374

 

SELECTED TALKS

Uddin, M. J., Taylor E. Kavanaugh, T. E., Crews, B. C., Duvall, C. L., and Marnett, L. J. “Water-soluble fluorocoxibs in detection of cyclooxygenase-2 in vivo.” World Congress in Drug Discovery and Therapeutics, Boston, MA 2017.

Uddin, M. J., Crews, B. C., Ghebreselasie, K., Daniel, C.K., Marnett, L. J., “Activatable COX-2 Probes in Optical Imaging of Cancer.” ASBMB, San Diego, CA 2016.

Uddin, M. J., Crews, B. C., Uddin, M. I., Ghebreselasie, K., Daniel, C.K., Wilson, A. J., Nickels, M. L., Tantawy, M. N., Manning, H. C., Khalele, D., Marnett, L. J. “Targeted PET imaging of COX-1 in Ovarian Cancer.” World Molecular Imaging Congress, Honolulu HI 2015.

Uddin, M. J., Crews, B. C., Uddin, M. I., Ghebreselasie, K., Daniel, C.K., Wilson, A. J., Nickels, M. L., Tantawy, M. N., Manning, H. C., Khalele, D., Marnett, L. J. “Targeted PET imaging of COX-1 in Ovarian Cancer.” Frontiers of Biomedical Imaging, VUIIS Nashville TN 2015

ORAL TALK - Uddin, M. J.; Brenda C. Crews; et al. “Flurocoxib C. A long-lived NIR COX-2 Probe enabling selective visualization of inflammation and cancer” International Conference of Radiology and Imaging, Chicago, IL 2013

INVITED SPEAKER - Uddin, M. J.; Brenda C. Crews; et al. “A novel approach to biomolecular imaging of COX-2” AACR Frontiers in Cancer Research, Anaheim CA 2012

ORAL TALK - Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 inhibitors in PET imaging of inflammation and cancer” AACR-ACS Meeting – Chemistry in Cancer Research, San Diego CA 2011

Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“Near-infrared fluorescence imaging of inflammation and cancer” NCI Translates, Washington DC  2011

Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“18F-Labeled COX-2 inhibitors in PET imaging of inflammation and cancer ” Frontiers of Biomedical Imaging, VUIIS 2011

Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“Rhodamine-based new fluorophores for imaging” 6th Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2010

Uddin, M. J.; Crews, B. C.; Blobaum, A., Kingsley, P., Piston, D., Marnett, L. J. “NASIDs in Cancer Detection” NCI Translates, VA  2009

ORAL TALK - Uddin, M. J.; Crews, B. C.; Marnett, L. J. “Cytostatic activity of NSAID-Podophylotoxin conjugates” 11th International Conference — Bioactive Lipids in Cancer, Inflammation and Related Diseases, Cancun, Mexico 2009

Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 targeted toxic agents” 5th Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2009

Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“COX-2 targeted fluorescent Imaging agents” Frontiers of Biomedical Imaging, VUIIS 2008

Uddin, M. J.; Brenda C. Crews; Dannenberg, A. J., Subbarahmiah, K.; Marnett, L. J. “COX-2 targeted Imaging of Cancer” 6th AACR International Conference on Frontiers in Cancer Prevention Research, Philadelphia PA, 2007

Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“COX-2 targeted Therapeutic Agents” 3rd Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2007

Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 targeted Molecular Imaging Agents” 2nd Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2006

Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “Fluorescent Derivatives of Indomethacin as Selective Inhibitor of Cyclooxygenase-2.” U54 Network in Translational Research in Optical Imaging Retreat, Stanford University, California 2005

ORAL TALK -  Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. “Design of Selective Cyclooxygenase-2 Inhibitors.” Drug Discovery 2004 Lecture Series, University of Alberta Canada 2004

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.“Design and Synthesis of Acyclic Triaryl Olefins: A New Class of Highly Potent and Selective Cyclooxygenase-2 (COX-2) Inhibitors.” 12th Symposium on Organo-Metallic Chemistry Directed Toward Organic Synthesis (OMCOS 12), Toronto University, Toronto, Canada 2003

Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. “Design, Synthesis and Biological Evaluation of Novel Celecoxib and Rofecoxib Analogs as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide and Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre.” 5th Annual Symposium of Canadian Society for Pharmaceutical Sciences, Banff Center, Alberta, Canada 2002

ORAL TALK - Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Yamamoto, I. “Synthesis of Isoxazolidine fused Heterocycles from Diastereoselective Intramolecular 1,3-Dipolar Cycloaddition of Nitrones.” 76th Annual Meeting of the Chemical Society of Japan, Kanagawa, Japan 1999